Coya Therapeutics, Inc. Common Stock (COYA)

Coya Therapeutics, Inc. Common Stock (COYA) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $116M; returns 1 day -4.8%, 1 week -7.3%, 1 year -43.6%.

Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative, autoimmune, and metabolic diseases by targeting the biology of regulatory T cells (Tregs). The company's core thesis is that restoring the function of dysfunctional Tregs can suppress systemic inflammation and neuroinflammation, which are underlying drivers of these conditions.

Groups COYA belongs to

• Healthcare
• Biotechnology
• Clinical Stage Biotech
• Clinical Stage
• Neuroscience
• Neurological Disorders
• Autoimmune Diseases
• Biologics
• Metabolic Disorders
• Chronic Inflammatory Diseases
• Pharmaceuticals

COYA financial model: income statement, cash flow and balance sheet